EcoDrugPlus

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSACLG00000017731
Gene Symbol: EGLN2
3 Cross references
195 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSACLG00000007509
Gene Symbol: EGLN3
3 Cross references
199 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSACLG00000027698
Gene Symbol: EPAS1
3 Cross references
211 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSACLG00000002056
Gene Symbol: ECE1
1 Cross references
230 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSACLG00000025655
Gene Symbol: EDNRA
3 Cross references
205 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSACLG00000007283
Gene Symbol: EDNRB
1 Cross references
200 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSACLG00000016687
Gene Symbol: EDNRB
3 Cross references
178 Possible Orthologues:

Endothelin Receptor Type B-Like

Ensembl ID : ENSACLG00000011966
Gene Symbol: LOC113017201
4 Cross references
201 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSACLG00000023070
Gene Symbol: EZH2
3 Cross references
240 Possible Orthologues:

Eph Receptor B4b

Ensembl ID : ENSACLG00000011687
Gene Symbol: EPHB4B
1 Cross references
166 Possible Orthologues:

Ephrin Type-B Receptor 4-Like

Ensembl ID : ENSACLG00000008110
Gene Symbol: LOC113015903
3 Cross references
166 Possible Orthologues:

Epidermal Growth Factor Receptor-Like

Ensembl ID : ENSACLG00000015280
Gene Symbol: LOC113010022
3 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).